Watchmaker Genomics has collaborated with Revvity to automate its DNA and RNA library preparation kits for NGS workflows on the Sciclone™ G3 NGSx platform.

Biodesix, in partnership with Bio-Rad, contributed to the ctMoniTR Project, which demonstrated that changes in circulating tumor DNA (ctDNA) can predict cancer treatment outcomes.

A new study highlights IsoPSA’s ability to identify low-risk prostate cancer patients who can avoid unnecessary interventions. The test also helps monitor high-risk patients more closely.

ProBioGen’s GlymaxX technology supports the FDA-approved Ziihera® antibody for HER2-positive biliary tract cancer, advancing targeted therapies.

Seer, Inc. (Nasdaq: SEER), announced that the company will showcase new findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia, PA, from February 22-26, 2025.

Dovetail Genomics, announces the availability of its early access services for FFPE (Formalin-Fixed Paraffin-Embedded) sample analysis, offering new capabilities for detecting structural variants and profiling RNA in oncology research.

BIOHIT HealthCare is pleased to announce that a clinical study conducted by Homerton University Hospital NHS Foundation Trust, London, has confirmed the diagnostic accuracy of GastroPanel in identifying gastric cancer risk in patients.

Celonic Group, a “Pure Play” biologics contract development and manufacturing organization (CDMO), announced the signing of a multi-year commercial manufacturing agreement with LINDIS Biotech.

AMSBIO has launched MatriMix for PDX, a fully defined extracellular matrix (ECM) hydrogel comprising of collagen, laminin-511 E8 fragments and hyaluronic acid optimized to support patient-derived xenograft (PDX) studies.

Bio-Rad leads investment to support the launch of ColoSense®, a non-invasive colorectal cancer screening test, and advance diagnostic innovations for inflammatory bowel disease.